Skip to Content

Antibodies, Volume 4, Issue 3

2015 September - 8 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (8)

  • Review
  • Open Access
97 Citations
42,859 Views
19 Pages

Antibody Fragments and Their Purification by Protein L Affinity Chromatography

  • Gustav Rodrigo,
  • Mats Gruvegård and
  • James M. Van Alstine

11 September 2015

Antibodies and related proteins comprise one of the largest and fastest-growing classes of protein pharmaceuticals. A majority of such molecules are monoclonal antibodies; however, many new entities are antibody fragments. Due to their structural, ph...

(This article belongs to the Special Issue Antibody Constructs)
  • Review
  • Open Access
39 Citations
15,796 Views
19 Pages

1 September 2015

At 420 million years, the variable domain of New Antigen Receptors or VNARs are undoubtedly the oldest (and smallest) antigen binding single domains identified in the vertebrate kingdom. Their role as an integral part of the adaptive immune system of...

  • Review
  • Open Access
14 Citations
12,416 Views
15 Pages

B Cell Epitope-Based Vaccination Therapy

  • Yoshie Kametani,
  • Asuka Miyamoto,
  • Banri Tsuda and
  • Yutaka Tokuda

14 August 2015

Currently, many peptide vaccines are undergoing clinical studies. Most of these vaccines were developed to activate cytotoxic T cells; however, the response is not robust. Unlike vaccines, anti-cancer antibodies based on passive immunity have been ap...

  • Review
  • Open Access
103 Citations
33,691 Views
28 Pages

Antibody Conjugates: From Heterogeneous Populations to Defined Reagents

  • Patrick Dennler,
  • Eliane Fischer and
  • Roger Schibli

3 August 2015

Monoclonal antibodies (mAbs) and their derivatives are currently the fastest growing class of therapeutics. Even if naked antibodies have proven their value as successful biopharmaceuticals, they suffer from some limitations. To overcome suboptimal t...

  • Review
  • Open Access
8 Citations
12,043 Views
27 Pages

15 July 2015

Assembly of misfolded proteins into fibrillar deposits is a common feature of many neurodegenerative diseases. Developing effective therapies to these complex, and not yet fully understood diseases is currently one of the greatest medical challenges...

  • Article
  • Open Access
106 Citations
25,796 Views
16 Pages

Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®

  • Sven Hoefman,
  • Ingrid Ottevaere,
  • Judith Baumeister and
  • Maria Laura Sargentini-Maier

10 July 2015

Nanobodies are antigen-binding, single variable domain proteins derived from naturally-occurring, heavy chain only antibodies. They are highly soluble, stable, and can be linked to build multi-specific formats. Several Nanobodies are currently in cli...

  • Article
  • Open Access
9 Citations
7,944 Views
13 Pages

10 July 2015

Monoclonal antibodies are generally produced using a generic platform approach in which several chromatographic separations assure high purity of the product. Dimerization can occur during the fermentation stage and may occur also during the downstre...

XFacebookLinkedIn
Antibodies - ISSN 2073-4468